And University of Oxford nutrition and population health professor Susan Jebb said.
She then questioned if governments and businesses funding weight reduction drugs like these were worth it given people would eventually have to deal with the health issues resulting from obesity.
She said: “Is it going to be worth the [British] National Health Service investing in these meds if people just have them for a short time and then they load all the weight back on.
Or does the NHS have to understand that these are going to be long-term treatments?
” Either individuals truly have to accept this as a treatment for life, or we in science need to think really, really hard, how to support people when they stop the drug.”
